You are here

Strain-Independent Therapeutic Antibodies for Influenza

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44AI106077-05
Agency Tracking Number: R44AI106077
Amount: $2,998,485.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: PA18-574
Solicitation Year: 2018
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-02-06
Award End Date (Contract End Date): 2023-01-31
Small Business Information
1505 OBRIEN DR # B
Menlo Park, CA 94025-1435
United States
DUNS: 962700048
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (415) 722-4305
Business Contact
Phone: (650) 616-1100
Research Institution

In this Phase IIB proposal, we seek funding to complete the IND-enabling development of CF-404, a mixture of
three native human monoclonal antibodies (mAbs). Activity has been established in mouse models against
representatives of all major circulating strains of influenza A and B. By providing a pan-influenza treatment, we
avoid delays associated with strain typing, with improved outcomes expected from the prompt treatment. We
specifically propose here to address regulatory issues relating to delivery of the mAb mixture by inhalation. Our
background work demonstrated that inhaled delivery provides superior efficacy compared to systemic delivery,
at ~10-fold lower dose. The inhalation technology from industry leader Aerogen Pharma is established as
suitable for hospitalized patients, including those on a ventilator. Due to drug resistance to the existing influenza
therapeutic drugs, there is a high need for our product. The first class of small molecule therapeutics, the
amantadines, are now largely useless due to drug resistance. The second class, neuraminidase inhibitors, are
currently experiencing similar emergence of resistance. The newest class, polymerase inhibitors, has already
shown worrisome signs of early emergence of drug resistant strains (10% in the Phase 3 trials). By contrast,
intensive selection in vitro for virus that escapes our mAbs has shown that resistance is likely to be far less
common than for the small molecule antivirals. The impact of CF-404 is thus expected to be high.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government